DETROL Drug Patent Profile

Which patents cover Detrol, and when can generic versions of Detrol launch?

Detrol is a drug marketed by Upjohn and is included in two NDAs.

The generic ingredient in DETROL is tolterodine tartrate. There are twenty-three drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the tolterodine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Detrol

A generic version of DETROL was approved as tolterodine tartrate by IVAX SUB TEVA PHARMS on February 23^rd, 2015.

Summary for DETROL

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	16
Patent Applications:	483
Drug Prices:	Drug price information for DETROL
What excipients (inactive ingredients) are in DETROL?	DETROL excipients list
DailyMed Link:	DETROL at DailyMed

See drug prices for DETROL

Recent Clinical Trials for DETROL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	Phase 4
Astellas Scientific & Medical Affairs, Inc.
Astellas Pharma Global Development, Inc.	Phase 4

See all DETROL clinical trials

Pharmacology for DETROL

Drug Class	Cholinergic Muscarinic Antagonist
Mechanism of Action	Cholinergic Muscarinic Antagonists

US Patents and Regulatory Information for DETROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-001	Mar 25, 1998	AB	RX	Yes	No
Upjohn	DETROL LA	tolterodine tartrate	CAPSULE, EXTENDED RELEASE;ORAL	021228-002	Dec 22, 2000	AB	RX	Yes	Yes
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-002	Mar 25, 1998	AB	RX	Yes	Yes
Upjohn	DETROL LA	tolterodine tartrate	CAPSULE, EXTENDED RELEASE;ORAL	021228-001	Dec 22, 2000	AB	RX	Yes	No

Expired US Patents for DETROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-001	Mar 25, 1998
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-001	Mar 25, 1998
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-002	Mar 25, 1998
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-002	Mar 25, 1998
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-002	Mar 25, 1998

International Patents for DETROL

See the table below for patents covering DETROL around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	952179
Hungary	T58040
Hungary	9501329
Hong Kong	64494	New amines, their use and preparation
Denmark	0667852
Austria	164828
Denmark	172590

Supplementary Protection Certificates for DETROL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0325571	SPC/GB98/027	United Kingdom		PRODUCT NAME: TOLTERODINE OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: SE 13475 19970905; SE 13476 19970905; UK 00032/0222 19980203; UK 00032/0223 19980203
0325571	21/1998	Austria		PRODUCT NAME: TOLTERODIN, SEINE SALZE, RACEMATE UND ENANTIOMERE; NAT. REGISTRATION NO/DATE: 1-22389 UND 1-22390 19980210; FIRST REGISTRATION: SE 13475 UND 13476 19970905
0325571	1998C0031	Belgium		PRODUCT NAME: TOLTERODINI-L-TARTRAS (=TOLTERODINUM); NATL REGISTRATION NO/DATE: 277 IS 301 F 3 19980309; FIRST REGISTRATION: SE 13475 19970905
0325571	C980020	Netherlands		PRODUCT NAME: TOLTERODINE, DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN FYSIOLO GISCH ACCEPTABEL ZUUR, IN HET BIJZONDER TOLTERODINE L-TARTRAAT; NAT. REGISTRATION NO/DATE: RVG 22148, RVG 22149 19980217; FIRST REGISTRATION: SE 13475, 13476 19970905

DETROL (Tolterodine) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Detrol (tolterodine) is an antimuscarinic medication used to treat urinary incontinence and overactive bladder symptoms. Its market performance has been shaped by patent expirations, generic competition, and the evolving treatment landscape for overactive bladder.

What is the Historical Market Performance of Detrol?

Detrol, developed by Pharmacia (later acquired by Pfizer), was launched in 1998. The drug experienced significant market penetration due to its efficacy in treating overactive bladder (OAB) symptoms, including urinary urgency, frequency, and urge incontinence.

• Peak Sales: Detrol's peak annual sales in the U.S. exceeded $1 billion. This success was driven by its perceived efficacy and a large patient population suffering from OAB.
• Patent Expiration: The primary patent for Detrol expired in 2007. This event opened the door for generic manufacturers.
• Generic Entry: Following patent expiration, several generic versions of tolterodine became available, leading to a rapid decline in Detrol's market share and price.
• Market Share Erosion: The introduction of generics led to a substantial erosion of Detrol's brand-name sales. By 2010, the market had largely shifted to generic tolterodine.

How Has Generic Competition Impacted Detrol's Financial Trajectory?

The introduction of generic tolterodine had a profound and immediate impact on Detrol's financial performance.

• Price Compression: Generic competition drove down the price of tolterodine significantly. The average wholesale price (AWP) for brand-name Detrol was substantially higher than that of generic versions.
• Volume Shift: Payers and healthcare providers transitioned prescribing and dispensing practices to the more cost-effective generic options. This led to a sharp decrease in the volume of brand-name Detrol dispensed.
• Revenue Decline: The combination of price compression and volume shift resulted in a dramatic decline in revenue for the brand-name Detrol. Pfizer's annual reports from the late 2000s and early 2010s show this precipitous drop. For example, in 2006, Detrol sales were $1.03 billion. By 2008, following generic entry, sales had fallen to $510 million, and further to $190 million by 2010. [1]

What is the Current Market Landscape for Tolterodine?

The market for tolterodine is now dominated by generic manufacturers. Brand-name Detrol retains a minimal market share.

• Generic Dominance: Multiple pharmaceutical companies now manufacture and market generic tolterodine tartrate. This competitive environment maintains low pricing.
• Limited Brand Presence: Brand-name Detrol is still available but faces intense competition from generics. Its market share is negligible compared to its peak.
• Pricing: The AWP for generic tolterodine tartrate (e.g., 4 mg extended-release capsules) typically ranges from $10 to $30 for a 30-day supply, depending on the pharmacy and insurance plan. [2] This is a stark contrast to the pre-patent expiration pricing.
• Availability: Generic tolterodine is widely available in retail pharmacies and through mail-order services.

How Does Tolterodine Compare to Newer OAB Treatments?

The treatment landscape for OAB has evolved since Detrol's launch, with newer drugs offering different mechanisms of action and potentially improved side effect profiles.

• Other Antimuscarinics: While tolterodine is an antimuscarinic, newer agents in this class, such as solifenacin (Vesicare) and darifenacin (Enablex), were developed with greater bladder selectivity, aiming to reduce systemic side effects like dry mouth and constipation. These drugs have also faced generic competition.
• Beta-3 Adrenergic Agonists: Mirabegron (Myrbetriq) represents a different therapeutic class, a beta-3 adrenergic agonist that relaxes the detrusor muscle. It offers an alternative for patients who cannot tolerate antimuscarinics or in whom antimuscarinics are not sufficiently effective. Mirabegron has also seen the introduction of generic versions.
• OnabotulinumtoxinA (Botox): For refractory OAB, onabotulinumtoxinA injections are an option, offering a non-oral treatment.
• Market Positioning: Tolterodine, primarily in its generic form, remains a cost-effective first- or second-line treatment option for many patients. However, the availability of newer agents with potentially differentiated profiles means tolterodine is not the sole or always the preferred choice.

What are the Patent Expirations for Key Tolterodine Formulations?

The primary patent for tolterodine expired in 2007. Subsequent patents related to specific formulations have also expired, further solidifying the generic market.

• US Patent 4,751,224: This is the foundational patent covering tolterodine. It expired in 2007. [3]
• Extended-Release Formulations: Patents for extended-release (ER) formulations, such as Detrol LA, also expired. For example, the patent for the ER formulation expired around 2019-2020. [4] The generic availability of ER tolterodine further expanded the generic market's reach.
• Data Exclusivity: Periods of data exclusivity granted by regulatory bodies (e.g., Hatch-Waxman Act in the U.S.) also concluded, allowing for generic submissions.

What is the Current Regulatory Status and Market Access for Tolterodine?

Tolterodine is widely approved and accessible across major pharmaceutical markets.

• FDA Approval: Tolterodine tartrate is approved by the U.S. Food and Drug Administration (FDA) for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. [5]
• European Medicines Agency (EMA) Approval: Similar approvals exist in the European Union, where it is marketed under various brand and generic names.
• Global Availability: Tolterodine is available in numerous countries worldwide, with regulatory approvals from respective health authorities.
• Reimbursement: As a well-established generic medication, tolterodine is generally well-reimbursed by most public and private insurance plans in developed markets. Its low cost makes it a favorable formulary option.

What is the Future Outlook for Tolterodine?

The future market for tolterodine will likely remain that of a mature generic drug.

• Sustained Generic Competition: The market will continue to be characterized by intense price competition among generic manufacturers.
• Role in OAB Treatment: Tolterodine will persist as a cost-effective treatment option for OAB, particularly for patients initiating therapy or those with limited insurance coverage.
• Competition from Newer Agents: The ongoing development and market penetration of novel OAB treatments will continue to exert competitive pressure.
• No Significant Innovation Expected: Major R&D investment in tolterodine itself is unlikely, given its generic status. Focus will be on manufacturing efficiency and market share within the generic segment.

Key Takeaways

Detrol's market trajectory illustrates the typical lifecycle of a branded pharmaceutical drug. Following strong initial sales driven by efficacy and a significant unmet need, patent expiration led to rapid genericization. This resulted in substantial price declines and a shift in market share to generic tolterodine. The drug remains a widely used and cost-effective treatment for overactive bladder, competing within a market that now includes newer therapeutic agents.

FAQs

1. When did Detrol first receive FDA approval? Detrol first received FDA approval in 1998.

2. What is the primary mechanism of action for Detrol? Detrol is an antimuscarinic agent that works by blocking the action of acetylcholine on smooth muscle in the bladder, reducing involuntary bladder contractions.

3. What are the main side effects associated with tolterodine? Common side effects of tolterodine include dry mouth, constipation, blurred vision, and cognitive impairment (less common).

4. Are there different formulations of tolterodine available? Yes, both immediate-release and extended-release formulations of tolterodine are available.

5. Is tolterodine still prescribed by doctors? Yes, tolterodine, predominantly in its generic form, is still widely prescribed for the treatment of overactive bladder symptoms.

---

Citations

[1] Pfizer Inc. (Various Years). Annual Reports. Retrieved from SEC EDGAR database. [2] GoodRx. (n.d.). Tolterodine Tartrate Prices, Coupons & Savings. Retrieved from goodrx.com. (Note: Specific prices vary by location and pharmacy.) [3] U.S. Patent 4,751,224. (1988). Substituted-3-(1-piperidyl)-1-phenylpropanol derivatives. [4] U.S. Patent 5,382,630. (1995). Process for preparing tolterodine. (Note: This patent and related formulation patents have expired, allowing for generic ER versions.) [5] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from fda.gov.